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Summary We investigated the ability of high concentrations of oestradiol to reverse the growth inhibitory
action of tamoxifen on MCF-7 breast cancer cells in vivo. Tamoxifen inhibits the oestradiol stimulated growth
of MCF-7 cells in athymic mice. Using a sustained release preparation of tamoxifen we consistently achieved
serum concentrations of the drug in the 40 to 50 ngml ' range and much higher levels in tissues. These serum
levels are sufficient to inhibit the oestrogen stimulated growth of MCF-7 tumours exposed to physiologic (i.e.
300-600pgml-' serum oestradiol concentrations). However, by administering dosages that increase serum
oestradiol concentrations to 900-2000 pg ml ', mimicking the increase often observed clinically in
premenopausal women taking tamoxifen, we show that the growth inhibitory action of tamoxifen can be
partially reversed. Serum tamoxifen levels were elevated to nearly 400 ng ml' by injecting 1 mgday-'
tamoxifen (IP 3 x weekly); this dosage was more effective at inhibiting oestradiol stimulated tumour growth
than subcutaneous tamoxifen capsules alone. Our data suggest that at low serum levels tamoxifen may not act
optimally. There may be a need to monitor tamoxifen levels in premenopausal patients to ensure that they are
high enough not to be overcome by a tamoxifen induced increase in ovarian steroidogenesis.
Tamoxifen, a non-steroidal antioestrogen, is the first line
antihormonal therapy for breast cancer. Tamoxifen was orig-
inally introduced to treat advanced breast cancer in post-
menopausal patients (Cole et al., 1971), however the drug has
proved to be effective in premenopausal patients as well
(Buchanan et al., 1986; Ingle et al., 1986; Manni & Pearson,
1980; Sawka et al., 1986). Recently tamoxifen has been
evaluated as an adjuvant therapy in premenopausal women
with either node positive (CRC Adjuvant Breast Trial Work-
ing Party, 1988; Nolvadex Adjuvant Trial Organization,
1988) or node negative disease (Breast Cancer Trials Com-
mittee, Scottish Cancer Trials Office, 1987; CRC Adjuvant
Breast Trial Working Party, 1988; Fisher et al., 1989). An
early analysis of the clinical trials data demonstrates an
increase in disease free survival in those women receiving the
antioestrogen. Indeed the use of tamoxifen is being extended
to treat normal premenopausal women to evaluate whether
an antioestrogen can prevent breast cancer (Powles et al.,
1990). However, the question can be asked whether antioest-
rogen therapy in premenopausal women is an optimal
strategy. Tamoxifen is known to cause an elevation in
ovarian steroidogenesis whether given in a short course
(Groom & Griffiths, 1976; Senior et al., 1978) or as con-
tinuous therapy (Jordan et al., 1987; Jordan et al., 1991;
Manni et al., 1979; Sherman et al., 1979). Clearly, if tamox-
ifen is a competitive inhibitor of oestrogen action through the
oestrogen receptor, then an increase in oestrogen levels might
reverse the antitumour action of tamoxifen. We have add-
ressed this question in a laboratory model. Tamoxifen
inhibits the oestrogen-stimulated growth of tumours derived
from the MCF-7 breast cancer cell line that have been
inoculated into athymic mice (Gottardis et al., 1988). We
have now evaluated the relative ability of oestradiol and
tamoxifen to control the growth of MCF-7 tumour cells in
vivo. The significance of our findings is discussed in its
clinical context.
Materials and methods
Tumours
MCF-7 breast tumours were maintained as serially passaged
solid tumours in ovariectomised athymic nude mice (Harlan-
Sprague Dawley, Madison, WI), bearing 1.0 cm oestradiol
capsules (described below). Tumours were routinely passaged
by removing a > 1.0 cm diameter tumour from an oestradiol
treated animal, trimming away all fat, skin, and necrotic
tissue, and mincing the remaining viable tissue into pieces of
approximately 1 mm3 in a bath ofcold CMF-HBSS. Tumour
pieces were then implanted into the thoracic mammary fat
pads (1/side) of 4 to 5 week old athymic mice by using a 13
gauge trocar. At the time of tumour transplantation, all
animals were also implanted subcutaneously with a 1.0 cm
Silastic capsule containing 17P-oestradiol (described below).
Tumour measurements were performed weekly using cali-
pers. Tumour cross sectional areas were calculated using the
formula:
(length/2 x width/2) x 1
After 5 weeks of oestrogen treatment, tumours had reach-
ed an average size of 0.5 cm2. Animals were then randomised
into six groups, and the oestradiol capsules were removed.
All of the animals in each group then received one of the
following treatments: a 1.0cm oestradiol capsule, a 2.0cm
tamoxifen capsule, or a 2.0 cm tamoxifen capsule plus either
a 1.7 mg oestradial pellet, or a 2.0 cm, 1.0 cm or 0.5 cm
oestradiol capsule. Tumour cross sectional areas were record-
ed for each animal, means for each time point were calcu-
lated and then standardised to be expressed as a percentage
of the tumour area at the outset of treatment. Standard
errors were calculated from these standardised tumour areas.
In another experiment athymic mice (18) bitransplanted
with MCF-7 tumours were treated with oestradiol (1 cm
silastic capsule) until the tumour areas were approximately
0.6 cm2. Animals were divided into three groups of six mice:
oestradiol alone, oestradiol plus a 2 cm tamoxifen implant or
oestradiol, tamoxifen (2 cm capsule) and tamoxifen 1 mg IP
3 x per week (MWF).
Tumours were measured for 4 weeks, after which animals
were sacrificed and tissues were taken for determination of
tamoxifen. Oestrogen and progesterone receptors were deter-
mined by immunoassay using ER-EIA and PR-EIA kits
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(Abbot Laboratories, Chicago, IL). Assays were performed
following the standard kit protocol, except that tumours were
homogenised in buffer containing 0.4 M KCI during cytosol
preparation.
Lb w
+1
E
0)
0)
0)
E
0)
co
Drug administration
Oestradiol was administered by subcutaneous implantation
of either Silastic capsules or sustained release cholesterol
pellets containing 1.7 mg oestradiol (Innovative Research of
America, Toledo, OH). Tamoxifen was administered by
either subcutaneous implantation of a Silastic capsule or IP
injection.
Silastic capsules were prepared by plugging one end of
various length pieces of medical grade Silastic tubing (0.078
in ID by 0.125 in OD; Dow corning, Midland, MI) with
Silastic silicone type A medical adhesive (Dow Coming) and
then filling with either crystalline tamoxifen - free base
(Sigma Chemical Co., St Louis, MO) or 17P-oestradiol
(Sigma) mixed 1:3 (w/w) with silastic 382 medical grade
elastomer (Dow Corning) without catalyst. Capsules were
completed by filling the open end with adhesive and sterilis-
ing with radiation (>200 Gy).
Tamoxifen injections (IP) were prepared with 1 mg in
0.1 ml peanut oil. The tamoxifen was added to the required
volume of peanut oil and mixed with ethanol to aid solution.
The ethanol was evaporated under N2 with gentle heating
(50-60°C) on a mantle.
Oestradiol and tamoxifen measurements
Circulating 17p-oestradiol and tamoxifen levels were mea-
sures as previously described (Jordan et al., 1987; Langan
Fahey et al., 1990) in serum samples taken from tumour
bearing mice. Blood samples were obtained by bleeding from
the eye orbit under light ether anaesthesia or at autopsy.
After clotting overnight, samples were centrifuged at 2,000g;
serum was removed and stored at - 20C until analysis.
Tamoxifen measurements in tissues were made using nor-
mal phase HPLC with fluorescent detection of the parent
compound and metabolites as previously described (Robin-
son et al., 1991).
Statistical analyses
All statistical calculations were performed using Minitab
version 6.1 (Minitab, Inc., State College, PA) on an IBM
PS/2 model 50Z or Tandy 3000 HD personal computer.
Results
Serum and tissue levels oftamoxifen in athymic mice during
treatment with a sustained release silastic capsule
In order to assess the efficacy of our sustained release pre-
paration of tamoxifen, non-tumour bearing athymic mice
were implanted with 2 cm tamoxifen capsules. At 2 week
intervals beginning 2 weeks after capsule implantation serum
specimens were obtained by drawing blood from the eye
orbit of a random sample of mice; a subset of the mice were
sacrificed and liver, uterus and muscle samples were collected
for analysis of tamoxifen concentration.
As Figure la shows, serum tamoxifen levels did not change
significantly, remaining around 30-40 ng ml-l (0.08-0.11
tAM) for the duration of treatment. Although a slight down-
ward trend was evident towards the end of the experiment,
none of the values were significantly different from each
other.
Figure lb shows the concentrations of tamoxifen in mus-
cle, liver and uterine tissue samples taken during the course
of the experiment. Tamoxifen levels in uterus and muscle
remained fairly constant, showing slight decreases over time,
possibly as drug levels in the capsules were gradually deplet-
ed. Mean tamoxifen levels in liver tissue, although fairly
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Figure 1 a, Serum levels of tamoxifen in non tumour bearing
mice in ngml- (mean±s.e.m.). Animals were implanted with a
2.0 cm sustained release tamoxifen capsule. Values in parentheses
are numbers of animals measured at each time point, numbers in
brackets are tamoxifen levels expressed as iLM concentrations. b,
Tamoxifen levels in iLgg- of tissue (mean±s.e.m.) in various
tissues of non tumour bearing mice. (A) uterus, (l) liver, (-)
muscle.
constant over time, showed much greater variability at each
time point than any of the other tissues examined. This may
be due to inter-animal variation in hepatic metabolic ability,
or variability in the efficiency of extraction of drug from the
lipid rich hepatic tissue. However, the internal enclomiphene
control used in the tamoxifen assay makes the latter possi-
bility relatively unlikely.
Partial reversal ofthe growth inhibitory action oftamoxifen on
breast tumours and uterine tissue in vivo by increasing serum
concentrations ofoestradiol
MCF-7 breast cancer cells, when injected into the mammary
fat pads of oestrogen treated ovariectomised athymic mice,
form tumours at high frequency. These tumours can be
serially transplanted into other oestradiol treated athymic
mice. However, if the oestradaiol was removed from animals
bearing these tumours and replaced with tamoxifen, or if the
tumours were left in an oestrogenised environment and
tamoxifen was added, tumour growth rate was reduced to
nearly zero (Figure 2). Moreover, if the amount of oestrogen
administered to tumour bearing animals was increased,
resulting in a corresponding increase in serum oestradiol
concentrations, the growth inhibitory effect of tamoxifen was
reversed, although even extremely large doses of oestrogen
did not return tumour growth rate to that seen in a tumour
exposed to oestradiol alone in the absence of tamoxifen
(Figure 2). Two-sample t-tests performed on mean relative
tumour areas from the final week ofthis experiment for every
possible pairing of groups show that the mean relative
tumour area for each group was significantly different from
every other group, with one exception. There was no statis-
tically significant difference between the mean relative
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Figure 2 Percent increase in mean tumour areas, plotted as
mean±s.e.m., of MCF-7 tumours grown in athymic mice treated
with various amounts of oestradiol, with or without tamoxifen.
(0) 1.0 cm oestradiol capsule alone, (0) 2.0 cm tamoxifen cap-
sule± 1.7mg E2 pellet, (A) 2.0cm tamoxifen capsule + 2.0cm
oestradiol capsule, (-) 2.0 cm tamoxifen capsule + 1.0 cm oestra-
diol capsule, (0) 2.0 cm tamoxifen capsule + 0.5 cm oestradiol
capsule, (A) 2.0 cm tamoxifen capsule alone. There were 10 mice
per group.
tumour areas for the groups treated with tamoxifen plus
either a 2.0 cm or a 1.0 cm oestradiol capsule.
Uterine wet weights were also measured in all test animals
at the end of the experiment. Only the highest dose of
oestradiol administered could partially reverse the inhibition
of uterine growth by tamoxifen (Figure 3). The antioestro-
genic action of sustained release preparations of tamoxifen in
the mouse uterus has previously been noted (Jordan et al.,
1990).
Oestradiol and tamoxifen concentrations in the serum and
various tissues ofexperimental animals
Table I shows the circulating levels of 17p-oestradiol and
tamoxifen detected in the serum of the animals in each group
in the variable oestrogen dose experiment. Significant differ-
ences in serum oestradiol concentrations between groups are
addressed individually in Table I. No significant differences
were detected among the serum tamoxifen levels in any of the
tamoxifen treated groups.
Mean tamoxifen levels in the serum as well as in several
tissues of animals in each experimental group receiving tamo-
xifen are shown in Figure 4. No significant differences were
detected among any of the experimental groups for any of
the tissues with one exception. Tamoxifen levels in the uteri
of animals receiving tamoxifen in conjunction with either an
oestradiol pellet or a 2.0 or 1.0 cm oestradiol capsule were
+ 2.0 cm tamoxifen capsule
Figure 3 Uterine wet weights (mean ±s.e.m.) of animals treated
with either a 1.0 cm oestradiol (E2) capsule alone or a 2.0 cm
tamoxifen capsule with or without various doses of E2. Uterine
weight significantly lower (P<0.05) than those of animals receiv-
ing 1.0 cm E2 capsules alone. Group contained 10 mice.
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Figure 4 Tamoxifen concentrations (ng ml-' or g + s.e.m.) in
tissues taken from animals treated with a 2.0 cm tamoxifen cap-
sule with or without simultaneous treatment with oestradiol
administered at various doses. Within each treatment group bars
represent, from left to right, serum, muscle, liver, uterus, or
tumour levels. Arrows indicate uterine tamoxifen levels in
animals in which tamoxifen was co-administered with either an
oestradiol pellet or a 2.0 or 1.0 cm capsule. Tamoxifen levels in
the uteri of these three groups are significantly lower (P<0.05)
than levels observed in animals receiving tamoxifen and no
oestrogen. No other significant differences in tamoxifen concent-
rations were found for other tissues among any of the groups.
Table I Serum oestradiol and serum tamoxifen levels in each experimental group
Group* Serum oestradiol (pgmlbI)** Serum tamoxifen (ngml11)***
1.0 cm capsule 755.8± 152.3 (n = 9)ta'bc' N/A
TAMtt + E2 pellet 1949.4± 557.7 (n = 8)a,b,c,d 47.14±8.19t
TAMtt + E2 2.0cm capsule 927.7±76.5 (n = lO)b.c,d 54.00±6.36
TAMtt + E2 1.0cm capsule 543.3±91.8 (n = IO)b,e,f 42.12±6.69
TAMtt + E2 0.5 cm capsule 365.2± 87.6 (n = 9)b,e,f.g 47.60±6.21
TAMtt alone 9.1±3.6 (n = IO)c,d,e,fg 52.07± 8.27
*All animals were treated with E2 1.0 cm capsules for the first 5 weeks and then were divided into six
groups. **Circulating 17p-oestradiol was measured by RIA 6 weeks after animals were divided into six
groups. ***Circulating tamoxifen was measured by HPLC fluorescence assay (Langan-Fahey et al.,
1990; Robinson et al., 1991) 6 weeks after animals were divided into six groups. tMean±s.e. ttTAM:
2.0 cm tamoxifen capsule. aE2 alone vs tamoxifen + E2 pellet, P = 0.073. bSignificantly different from
tamoxifen alone, P<0.01. cSignificantly different from tamoxifen +0.5 cm E2 capsule, P<0.05.
dSignificantly different from tamoxifen + 1.0 cm E2 capsule, P<0.05. eSignificantly different from
tamoxifen + 2.0 cm E2 capsule, P<0.005. fSignificantly different from tamoxifen + E2 pellet, PK0.05.
gSignificantly different from E2 alone, P<0.05.
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significantly lower than those in animals receiving only tamo-
xifen. It should also be noted that of all tissues measured,
tamoxifen levels were consistently highest in tumour tissue of
each experimental group.
Table II shows concentrations of tamoxifen and its princi-
pal metabolites in serum, muscle and tumour and oestradiol
concentrations in serum for the experiment in which animals
received either a 2 cm capsule as their only source of tamox-
ifen, or were also administered 1 mg IP injections of tamox-
ifen three times weekly. This dose of tamoxifen brought
about a 10 fold increase in serum levels, and was coupled
with greater than 20-fold increases in tamoxifen levels in
tumour tissue and nearly a 30 fold increase in tamoxifen
concentration in the non-oestrogen target muscle tissue.
In animals receiving high dose injections, detectable levels
of the metabolites, 4-hydroxytamoxifen and N-desmethyl
tamoxifen (N-des) were detectable (Table II) but at lower
concentrations than the parent compound.
Effect ofa dose increase oftamoxifen on oestradiol-stimulated
MCF-7 tumour growth andsteroid receptor content
Tumour cross sectional areas from MCF-7 bearing mice
treated with oestradiol alone, oestradiol plus a tamoxifen
capsule, or oestradiol with a tamoxifen capsule plus IP tamox-
ifen injections are shown in Figure 5. Although administra-
tion of tamoxifen capsules alone was sufficient to block
further increases in tumour size, even greater inhibtion, i.e., a
reduction in tumour area, was achieved by the administration
of a high dose of tamoxifen.
Figure 6 shows the amounts of oestrogen and progesterone
receptors measured in the tumours in this experiment. It is
apparent that though tamoxifen blocked the oestradiol
induced increase of progesterone receptor in tumour cells in a
dose dependent fashion, it also induced a dose dependent
increase in oestrogen receptor levels in these tumours.
Discussion
The aim of these experiments was to determine the effective-
ness of tamoxifen to control the growth of hormone respon-
sive MCF-7 tumours grown in athymic mice under high and
low oestrogen environments.
We used a sustained release method (Robinson & Jordan,
1989) to treat tumour bearing athymic mice with tamoxifen.
The level of oestradiol we selected was targeted to be within
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Figure 5 Tumour cross-sectional areas (mean ±s.e.m.) of
animals in the high dose tamoxifen experiment. (0) all animals
receiving I cm oestradiol capsules only prior to randomisation
into treatment groups, (U) animals treated with 1.0 cm oestradiol
capsules, (A) animals treated with 1.0 cm oestradiol and 2.0 cm
tamoxifen capsules, (0) animals treated with oestradiol and
tamoxifen capsules and also receiving tamoxifen, I mg IP 3 x /
week. There were 12 animals per treatment group.
the range normally observed in premenopausal patients dur-
ing tamoxifen therapy (500-900 pgml-'). Tamoxifen con-
trolled oestradiol stimulated growth; a result that parallels
clinical experience (Breast Cancer Trials Committee, Scottish
Cancer Trials Office, 1989; Buchanan et al., 1986; CRC
Adjuvant Breast Trial Working Party, 1988; Fisher et al.,
1989; Ingle et al., 1986; Manni & Pearson, 1980; Nolvadex
Adjuvant Trial Organization, 1988; Sawka et al., 1986).
Although the action of tamoxifen was reversed with increas-
ing circulating concentrations of oestradiol, the levels
required appeared to be at the top of the range observed
clinically in premenopausal women during tamoxifen therapy
(Groom & Griffiths, 1976; Jordan et al., 1987; Jordan et al.,
1991; Manni et al., 1979; Senior et al., 1978; Sherman et al.,
1979). Nevertheless the efficacy of tamoxifen seemed to be
optimal in a low oestrogen environment. Indeed it has been
suggested (Sawka et al., 1986) that ovarian steroids can
reverse the action of tamoxifen since some patients who
respond and then fail tamoxifen treatment can subsequently
Table II Serum and tissue levels of tamoxifen (TAM), metabolites (N-
desmethyltamoxifen (N-des), 4-hydroxytamoxifen (40HT)) and serum oestradiol (E2) in
animals receiving high doses of tamoxifen
Treatment
E2 E2 capsules + TAM E2 and TAM capsules
Tissue capsules capsules IP TAM injection
Serum E2 491 130 pgml- 304 ±23 pgml-' 228 ±21 pgml-
Serum TAM 0 38±3 ngml-' 370±30 ngml-'
(0.1 AM) (1.0 -tM) Serum 40HT 0 4±2 ngml- 98±26 ngml-
(0.01 JAM) (0.25jM) Serum N-des 0 0.5+0.1 ngml-' 247±35 ngml-'
(0.001 JAM) (0.7 AM)
Muscle TAM 0 240± 20 ng g-' 6,500± 1,700 ng g-'
0.65JAM) (17.5JuM)
Muscle 40HT 0 * 900± 200 ng g-
(2.3gM) Muscle N-des 0 * 3,800 ±900 ng g
(10.7gM) Tumour TAM 0 1,200±100 ng g- 26,400± 2,800 ng g-'
(3.22JM) (71.0 AM) Tumour 40HT 0 * 5,000±700 ng g-'
(12.9JAM) Tumour N-des 0 * 22,600± ngg-
(63.7JAM)
*Metabolite concentrations below the limit of assay detection.
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Figure 6 Oestrogen and progesterone receptor levels (±s.e.m.)
in tumours from animals treated with either oestradiol (E2) alone,
E2 plus a tamoxifen capsule, or E2 plus both a tamoxifen capsule
and injections (1 mg IP 3 x weekly). Shaded bars - oestrogen
receptor, striped bars - progesterone receptor. Five tumours were
assayed for the E2 group, 11 for the tamoxifen capsule group
alone, and eight for the high dose tamoxifen group.
respond to oophorectomy.
Serum levels of tamoxifen achieved by our sustained
release method (approximately 40 ngml-') were at the low
end of the range that we observe in patients during long term
adjuvant therapy with tamoxifen (Langan-Fahey et al., 1990).
However, even at these levels, extremely high serum concen-
trations of oestradiol were required to cause tumour growth
(Table I and Figure 2). It was encouraging to find that even
low circulating concentrations of tamoxifen were effective at
inhibiting tumour growth in the presence of concentrations
of oestradiol in excess of that observed in most premeno-
pausal women receiving tamoxifen, and that an increased
dose of tamoxifen was even more effective at inhibiting
tumour growth (Figure 5). These principles may translate
directly to the clinic. Perhaps premenopausal women taking
tamoxifen should be monitored to ensure that they have
circulating levels of tamoxifen in the 150-200 ngml1 range
- levels we have shown to be readily achievable (Langan
Fahey et al., 1990). If tamoxifen levels in this range can be
maintained, administration of an LHRH agonist (Robertson
et al., 1989; Walker et al., 1989) or oophorectomy in order to
lower serum oestradiol levels may be unnecessary.
It was interesting to observe that high concentrations of
tamoxifen were present in the tumour compared to the
serum. Tissues might be expected to accumulate tamoxifen
because the triphenylethylenes are highly (>98%) protein
bound. Unfortunately it is not possible to establish the pro-
portion of the antioestrogen that is bioavailable. Never-
theless, the surrounding tissue could act as a drug depot for
the target site. We noted that tamoxifen levels in the uterine
tissue of animals treated with the three highest doses of
oestrogen were significantly lower than levels seen in animals
receiving tamoxifen alone. It is unlikely that this difference is
due to competition for binding to the oestrogen receptor, as
the receptor is present only in femtomolar concentrations in
the tissue; consequently, changes in tissue sequestration due
only to the elimination of tamoxifen binding to the oestrogen
receptor could not be detected by our assay. It may be that
oestradiol causes a down-regulation of uterine antioestrogen
binding sites (Murphy & Sutherland, 1981), or otherwise
interferes with uterine retention of tamoxifen.
Tamoxifen is extensively metabolised in patients (Adam et
al., 1979; Daniel et al., 1981) to a principal metabolite N-
desmethyltamoxifen and a minor metabolite 4-hydroxy-
tamoxifen which has high affinity for the oestrogen receptor
(Jordan et al., 1977). The subcutaneous sustained release
preparation of tamoxifen does not produce the same meta-
bolite profile as that seen in patients. In fact tamoxifen was
the major triphenylethylene detected at a circulating level of
about 40ngml-' in all groups treated with tamoxifen cap-
sules. Serum metabolites were detectable at only very low
levels, and were not reliably detectable in tissues at all. In
animals receiving high dose injections, the metabolites are
detectable, as shown in Table II, but at a lower ratio to the
parent compound that we have previously demonstrated
(Robinson et al., 1991). This may be due to differences in the
method of drug administration, since in our previous paper,
the animals were dosed orally, whereas in these experiments
tamoxifen was administered intraperitoneally. A trend
towards lower serum oestradiol levels in animals treated with
tamoxifen compared to those in control mice is apparent
(Table II), but these differences did not reach statistical
significance at the P<0.05 level.
Low circulating concentrations (-40 ng ml') of tamox-
ifen inhibited MCF-7 tumour growth in a high oestrogen
environment (Figures 3 and 6) and caused an antiestrogenic
change in the tumour steroid receptor concentrations. Tamox-
ifen decreased the concentration of progesterone receptor
whilst causing an increase in the concentration of oestrogen
receptors. Oestrogen withdrawal caused a similar increase in
oestrogen receptors and decrease in progesterone receptors in
MCF-7 cells in vitro (Welshons & Jordan, 1987). Although
tamoxifen is known to increase progesterone receptors in
some target tissues in vivo and tumour cells in vitro (Campen
et al., 1985; Horwitz et al., 1978; Koseki et al., 1978) tamox-
ifen prevented oestrogen induced increases in MCF-7 tumour
progesterone receptor in vivo.
It has been previously reported that tamoxifen induces
ovarian steroidogenesis in premenopausal women. In this
report we have shown that increasing circulating levels of
oestradiol are capable of reversing the growth inhibitory
effect tamoxifen has on oestrogen responsive tissues, i.e.
tumour and uterine tissue in vivo. We believe that although
the high circulating levels of oestradiol required to interfere
with the effects of tamoxifen on breast tumour tissue in the
laboratory are at the high end of the range seen clinically,
these results should nevertheless be viewed with some interest
by the clinical community as they indicate a need to be aware
ofthe actual serum tamoxifen levels achieved in their patients
rather than only the dose administered.
We wish to thank the contributors to the Eileen Henrich Memorial
Fund at the UWCCC for their generosity in providing equipment for
the measurement of tamoxifen and its metabolites.
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